Cardio-Oncology is affiliated with the International Cardio-Oncology Society (ICOS).
Trastuzumab in patients with breast cancer and pre-existing left ventricular systolic dysfunction
Trastuzumab is one of the most effective treatments in HER-2 positive breast cancer patients. However, it is associated with development of cardiomyopathy/heart failure (HF) which is often a limiting side effe...